Compare SCLX & BOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | BOF |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.1M | 63.6M |
| IPO Year | 2020 | 2023 |
| Metric | SCLX | BOF |
|---|---|---|
| Price | $5.57 | $3.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 54.6K | 21.3K |
| Earning Date | 04-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,253,000.00 | $3,184,018.00 |
| Revenue This Year | $122.52 | N/A |
| Revenue Next Year | $186.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.20 |
| 52 Week Low | $4.20 | $1.93 |
| 52 Week High | $34.27 | $5.25 |
| Indicator | SCLX | BOF |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | N/A |
| Support Level | $5.48 | N/A |
| Resistance Level | $7.77 | N/A |
| Average True Range (ATR) | 0.39 | 0.00 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 11.55 | 0.00 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients. The products are mainly sold through three channels: branded retail snack products, private label products for retailers, and fruit and vegetable ingredients sold to food manufacturers.